Page last updated: 2024-11-02

oxidopamine and MS (Multiple Sclerosis)

oxidopamine has been researched along with MS (Multiple Sclerosis) in 2 studies

Oxidopamine: A neurotransmitter analogue that depletes noradrenergic stores in nerve endings and induces a reduction of dopamine levels in the brain. Its mechanism of action is related to the production of cytolytic free-radicals.
oxidopamine : A benzenetriol that is phenethylamine in which the hydrogens at positions 2, 4, and 5 on the phenyl ring are replaced by hydroxy groups. It occurs naturally in human urine, but is also produced as a metabolite of the drug DOPA (used for the treatment of Parkinson's disease).

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (50.00)18.2507
2000's1 (50.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
de Lago, E1
Fernández-Ruiz, J1
Ortega-Gutiérrez, S1
Cabranes, A1
Pryce, G1
Baker, D1
López-Rodríguez, M1
Ramos, JA1
Chelmicka-Schorr, E1
Arnason, BG1

Other Studies

2 other studies available for oxidopamine and MS (Multiple Sclerosis)

ArticleYear
UCM707, an inhibitor of the anandamide uptake, behaves as a symptom control agent in models of Huntington's disease and multiple sclerosis, but fails to delay/arrest the progression of different motor-related disorders.
    European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, 2006, Volume: 16, Issue:1

    Topics: 3,4-Dihydroxyphenylacetic Acid; Analysis of Variance; Animals; Arachidonic Acids; Brain Chemistry; D

2006
Nervous system-immune system interactions and their role in multiple sclerosis.
    Annals of neurology, 1994, Volume: 36 Suppl

    Topics: Animals; Animals, Newborn; Autoimmunity; Autonomic Nervous System Diseases; Comorbidity; Humans; Imm

1994